FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions

Medication SafetyHealthcare ProfessionalEducators and caregivers

Sep 1

Written By Denise Kolakowski

Approved uses also being limited to certain patients — Approved uses also being limited to certain patients

more from the fda

Denise Kolakowski

FDA’s National Center for Toxicological Research Celebrates Half a Century of Cutting-Edge Research

Teligent Pharma, Inc.’s Issues Voluntary Recall of Lidocaine HCl Topical Solution 4% (Lot # 14218, Exp. 09/2022) Due to Super Potency